Drug Trial Radar · NCT07546214
A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.
Last checked: Nov 20, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
575
Actual
Start
Oct 13, 2025
Primary completion
Mar 18, 2026
Study completion Mar 18, 2026
Sponsor
- Lead sponsor
- Sun Pharmaceutical Industries, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To demonstrate therapeutic equivalence and safety of Tapinarof Cream, 1% (Sun pharma Canada, Inc.) and Vtama® (Tapinarof) Cream, 1% in the treatment of plaque psoriasis.
Conditions
- Plaque Psoriasis
Interventions
Tapinarof Cream, 1%Drug
The investigational product will be self-applied topically to the affected areas of the face once daily in the evening for 84 consecutive days.
Vtama® (Tapinarof) Cream, 1%Drug
The investigational product will be self-applied topically to the affected areas of the face once daily in the evening for 84 consecutive days.
Placebo ControlDrug
The investigational product will be self-applied topically to the affected areas of the face once daily in the evening for 84 consecutive days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Demonstration in Therapeutic Equivalence & Safety of the Investigational ProductTime frame: Baseline to Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Pharmaceutical Industries, Inc.
Hawthorne, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.